Home>Topics>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Why Biogen Stock Is Still An Investment Opportunity

    Headlines

    Sun, 21 Sep 2014

    raised, for the second time, its 2014 guidance by a big margin. The Company Biogen Idec is one of the world's leading biotechnology companies. Biogen discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis

  2. Finding Small Cap Gems Within Biotech

    Headlines

    Fri, 19 Sep 2014

    get on a regular basis is what do I look for when identifying and purchasing off the radar small cap stocks especially in the biotech sector especially given a recent big win on a previously highlighted small cap play (See below). This makes sense as nothing

  3. Incyte: Increasing Sales, Deep Pipeline, Multiple Catalysts, With A Side Of M&A Chatter

    Headlines

    Fri, 19 Sep 2014

    Incyte is mentioned frequently as an acquisition target. Whether Incyte gets acquired or not it is still a very compelling biotech investment with growing sales, a deep pipeline with important catalysts approaching. Let's take a closer look... SALES

  4. Horizon Pharma finalizes acquisition of Irish biotech

    Headlines

    Fri, 19 Sep 2014

    Horizon Pharma (NASDAQ: HZNP ) shareholders approve its acquisition of Irish biotech Vidara Therapeutics. It plans to shift its domicile to Ireland today making it the first U.S. company to complete a tax inversion deal. Post your comment!

  5. Orexigen Therapeutics (OREX) Presents at Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

    Headlines

    Thu, 18 Sep 2014

    Presentation Steve Byrne - Bank of America Merrill Lynch Well welcome to the last session of the day. My name is Steve Byrne. I am a Biotech Analyst for BofA Merrill in New York. And it’s a pleasure for me to host Orexigen. Mark Booth, Chief Commercial Officer

  6. Update: Oncolytics Announced Data From Phase II Study, Shares Plummeted

    Headlines

    Thu, 18 Sep 2014

    By Andy Batts : Oncolytics Biotech (NASDAQ: ONCY ) announced overall and KRAS-mutated patient data from its Phase II pancreatic cancer study. It was a two

  7. Biotech IPOs open strongly

    Headlines

    Thu, 18 Sep 2014

    Two new biotechs open with strong up moves today: Foamix Pharmaceuticals (NASDAQ: FOMX ) is up  16%  from its $6 offer price on turnover of 13M shares. ProQR Therapeutics (NASDAQ: PRQR ) is up  32%  from its $13 offer price on turnover of 5.5M shares. Post your comment!

  8. Gilead: Still 50% Upside Left In The Stock

    Headlines

    Thu, 18 Sep 2014

    NASDAQ: GILD ) . The shares have had a big run since all biotech stocks had a "hiccup" in early March. However, they have ..... to have incited some trepidation among shareholders in this biotech juggernaut. (click to enlarge) These concerns appear to

  9. Gilead Sciences: The Recent Dip In Share Price Creates A Buying Opportunity

    Headlines

    Thu, 18 Sep 2014

    Inc. (NASDAQ: GILD ) is one of the best performers in the biotech industry. Gilead's shares have risen by an astonishing ..... outpacing both the S&P 500 Index's 10% return and the Nasdaq Biotechnology Index's 19% return. This extraordinary performance is

  10. After A 40% Sell-Off Following Good News, RXi Pharmaceuticals Is Incredibly Attractive

    Headlines

    Wed, 17 Sep 2014

    Pharmaceuticals (NASDAQ: RXII ) is an up-and-coming biotechnology company that has recently caught my eye after losing 40 ..... huge risks in investing in the small developmental-stage biotechnology companies. The pain of losing 40% is very real. But

« Prev12345Next »
Content Partners